PharmaLex GMBH
PharmaLex is a leading provider of specialized services for the pharma, biotech and medtech industries. We guide you from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technology-enabled solutions to support you through the entire product lifecycle. We deliver exceptional results — going above and beyond the standard to deliver tailor-made solutions worldwide. The PharmaLex Group now has over 2200 employees, with 64 offices in 31 countries and more than 1000 satisfied clients worldwide.
Company details
Find locations served, office locations
- Business Type:
- Service provider
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About Us
PharmaLex.
Confidence beyond compliance.
As the leading provider of specialized services for the pharmaceutical, biotech and medical device industries, compliance is our priority. But it doesn’t stop there.
When you work with us, you can feel confident that your needs have been met, your reputation has been protected, and your business objectives are on track.
Who is PharmaLex and what do we do?
As a specialized provider, the services PharmaLex offers are essential to enable companies to maximize their development process and reduce their time to market.
This animation will give you a short overview of who we are, what we do and how we can support your company.
PharmaLex Brings You Biopharma Excellence
Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.